Want to see CVRX full AI Analyst Report?
CVRX Stock Chart & Stats
$3.27
$0.14(2.95%)
At close: 4:00 PM EDT
$3.27
$0.14(2.95%)
Day’s Range― - ―
52-Week Range$1.26 - $11.30
Previous Close$4.88
Volume248.25K
Average Volume (3M)692.88K
Market Cap
$35.97M
Enterprise Value$131.09M
Total Cash (Recent Filing)$64.59M
Total Debt (Recent Filing)$59.39M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Nov 03, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding26,641,598
10 Day Avg. Volume552,790
30 Day Avg. Volume692,883
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.71
Price to Sales (P/S)3.27
P/FCF Ratio-4.54
Enterprise Value/Market Cap3.64
Enterprise Value/Revenue2.14
Enterprise Value/Gross Profit2.47
Enterprise Value/Ebitda-2.90
Forecast
1Y Price Target
$4.38Price Target Upside33.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.01
Revenue Forecast (FY)$58.96M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And U.S. ExpansionSustained U.S. revenue growth alongside more implanting centers and sales territories indicates expanding adoption of Barostim rather than reliance on a single account. A broader commercial footprint can support recurring procedure-related sales and improve the company’s ability to build durable market presence.
High Gross MarginsGross margins in the mid-to-high 80% range demonstrate attractive product economics and provide substantial revenue contribution after device costs. If maintained as volume grows, these margins can help fund commercial expansion, clinical evidence generation, and eventual progress toward operating profitability.
Improving Reimbursement SupportImproving payer approval and payment outcomes reduce a major adoption barrier for hospitals and physicians considering Barostim. More predictable reimbursement, including strong traditional Medicare payment and favorable Humana coverage, can support broader procedural access and longer-term commercial scaling.
Bears Say
Persistent Losses And Cash BurnContinued cash consumption means CVRx has not yet converted its attractive gross margins and revenue growth into self-funded operations. Persistent losses may require additional capital before break-even, limiting strategic flexibility and increasing the financial consequences of slower commercialization.
Weakened And More Leveraged Balance SheetHigher leverage combined with a reduced equity base leaves less room to absorb operating setbacks or fund growth internally. If cash burn continues, CVRx could face greater refinancing or dilution pressure, making its capital structure a meaningful constraint on long-term execution.
Commercial Execution WeaknessThe guidance reduction shows that sales-force onboarding, turnover, and uneven productivity are currently limiting conversion of market opportunity into revenue. These issues can delay center activation and adoption, weakening near-term growth while management works to stabilize commercial execution.
CVRx News
CVRX FAQ
What was CVRx’s price range in the past 12 months?
CVRx lowest stock price was $1.25 and its highest was $11.30 in the past 12 months.
What is CVRx’s market cap?
CVRx’s market cap is $35.97M.
When is CVRx’s upcoming earnings report date?
CVRx’s upcoming earnings report date is Nov 03, 2026 which is in 13 days.
How were CVRx’s earnings last quarter?
CVRx released its earnings results on Aug 06, 2026. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of -$0.525 by -$0.005.
Is CVRx overvalued?
According to Wall Street analysts CVRx’s price is currently Undervalued.
Does CVRx pay dividends?
CVRx does not currently pay dividends.
What is CVRx’s EPS estimate?
CVRx’s EPS estimate is -0.5.
How many shares outstanding does CVRx have?
CVRx has 26,641,598 shares outstanding.
What happened to CVRx’s price movement after its last earnings report?
CVRx reported an EPS of -$0.53 in its last earnings report, missing expectations of -$0.525. Following the earnings report the stock price went down -59.764%.
Which hedge fund is a major shareholder of CVRx?
Currently, no hedge funds are holding shares in CVRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CVRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.38 (33.79% Upside)
$4.38 (33.79% Upside)
Blogger Sentiment
Neutral
CVRX Sentiment 67%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 15.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $73.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.22%
12-Months-Change
Fundamentals
Return on Equity
-152.35%
Trailing 12-Months
Asset Growth
-22.82%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CVRx
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
CVRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of meaningful commercial and clinical progress (16% Q2 revenue growth, improving margins, strong Medicare payment rates, favorable payer policy from Humana, BENEFIT‑HF trial momentum, and >18 months of cash) alongside material near‑term execution and market access headwinds (lowered full‑year revenue guidance, concentrated sales force turnover and productivity issues, significant denials from a major Medicare Advantage payer, a DOJ civil investigative demand, and a decline in European revenue). Management attributes the issues mainly to execution (onboarding and leadership gaps) and outlined targeted remediation actions, but the guidance cut and legal inquiry are notable negatives.View all CVRX earnings summariesCVRX Stock 12 Month Forecast
Average Price Target
$4.38
▲(33.79% Upside)
Technical Analysis
Ownership Overview
28.91% Insiders
6.18% Mutual Funds
31.32% Other Institutional Investors
27.25% Public Companies and
Individual Investors